{"id":"lmb-c","safety":{"commonSideEffects":[{"rate":null,"effect":"Vascular leak syndrome"},{"rate":null,"effect":"Hypoalbuminemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Elevated transaminases"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LMB-C is a recombinant immunotoxin composed of an anti-CD25 antibody fragment fused to a truncated Pseudomonas exotoxin. It binds to CD25 (IL-2 receptor alpha chain) on the surface of activated T cells and delivers the toxin intracellularly, causing cell death. This mechanism is designed to selectively eliminate CD25-positive malignant cells in T-cell lymphomas and leukemias.","oneSentence":"LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:13.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"},{"name":"Peripheral T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT01516580","phase":"PHASE3","title":"Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2011-12","conditions":"B-cell Non Hodgkin Lymphoma, Mature B-cell Leukemia Burkitt-type","enrollment":482},{"nctId":"NCT00057811","phase":"PHASE2","title":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-06","conditions":"Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma","enrollment":97},{"nctId":"NCT00002757","phase":"PHASE3","title":"TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-06","conditions":"Leukemia, Lymphoma","enrollment":1148},{"nctId":"NCT00162656","phase":"PHASE3","title":"Treatment of Mature B-cell Lymphoma/Leukaemia","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1996-05","conditions":"B-Cell Lymphoma","enrollment":848}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":510,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LMB C","genericName":"LMB C","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Peripheral T-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}